NCT07215026Completed
Understanding Non-small Cell Lung Cancer Patient Characteristics, Treatment Patterns and Outcomes
Understanding Non-small Cell Lung Cancer (NSCLC) Patient Characteristics, Treatment Patterns and Outcomes Via Cross-sEctional Physicians suRvey-based Chart Audit
Source: ClinicalTrials.gov · Last updated 10 Mar 2026
Brief summary (registry, in English)
This is a retrospective, cross-sectional, non-interventional, multi-country survey-based chart audit study to evaluate real-world treatment patterns, patient clinical profiles, and clinical outcomes among a NSCLC patients receiving at least 1L SACT (Systemic anticancer therapy)
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 833 (actual)
- First submitted
- 8 Oct 2025
- Start date
- 27 Oct 2025
- Primary completion date
- 21 Jan 2026
- Lead sponsor
- AstraZeneca
- Diseases
- Lung cancer, Childhood cancers
- NCT number
- NCT07215026
What you commit to
- Study type: Observational
- Participants enrolled: 833
- From 27 Oct 2025 to the primary completion date, 21 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Patient Eligibility Criteria - Inclusion Criteria Diagnosis: Confirmed de novo stage IIIB, IIIC, or IV NSCLC.
- Biomarker Status:
- Either: EGFR mutation present Or: No actionable gene alterations (AGAs) detected (including EGFR, ALK, ROS1, NTRK, BRAF V600E, RET, MET, KRAS, HER2; patients not tested for these also eligible).
- Treatment Start Window: Initiated 1L SACT (systemic anticancer therapy) for advanced NSCLC between the date of first Tagrisso® (osimertinib) approval for NSCLC in their country and 31 December 2024.
- Age: 18 years or older at time of 1L SACT initiation.
- \- Exclusion Criteria Concurrent Malignancies: Patients on active treatment for another primary malignancy at 1L SACT initiation.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | New Delhi | India | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.